secwatch.observer — SEC 8-K summary
======================================

Issuer:     Phio Pharmaceuticals Corp. (PHIO)
CIK:        0001533040
Form:       8-K
Filed at:   2024-05-28T23:59:59+00:00
Accession:  0001683168-24-003849
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Phio Pharma gets SMC OK to escalate PH-762 dose in Phase 1b; no dose-limiting toxicities
--------------------------------------------------------------------------------

- Safety Monitoring Committee recommended dose escalation to next concentration after initial cohort.
- No dose-limiting toxicities or clinically relevant treatment-emergent adverse events observed.
- PH-762 intratumoral injections were well tolerated in the first dose cohort.
- Phase 1b trial (NCT06014086) targets cutaneous squamous cell carcinoma, melanoma, Merkel cell carcinoma.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1533040/000168316824003849/0001683168-24-003849-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1533040/000168316824003849/phio_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-24-003849

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer